Therapy of adrenal insufficiency: an update

被引：0
作者：
Alberto Falorni
Viviana Minarelli
Silvia Morelli
机构：
[1] University of Perugia,Department of Internal Medicine, Section of Internal Medicine and Endocrine and Metabolic Sciences
来源：
Endocrine | 2013年 / 43卷
关键词：
21-Hydroxylase autoantibodies; ACTH; Addison’s disease; Congenital adrenal hyperplasia; Cortisone acetate; Fludrocortisone; Hydrocortisone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Adrenal insufficiency may be caused by the destruction or altered function of the adrenal gland with a primary deficit in cortisol secretion (primary adrenal insufficiency) or by hypothalamic-pituitary pathologies determining a deficit of ACTH (secondary adrenal insufficiency). The clinical picture is determined by the glucocorticoid deficit, which may in some conditions be accompanied by a deficit of mineralcorticoids and adrenal androgens. The substitutive treatment is aimed at reducing the signs and symptoms of the disease as well as at preventing the development of an addisonian crisis, a clinical emergency characterized by hypovolemic shock. The oral substitutive treatment should attempt at mimicking the normal circadian profile of cortisol secretion, by using the lower possible doses able to guarantee an adequate quality of life to patients. The currently available hydrocortisone or cortisone acetate preparations do not allow an accurate reproduction of the physiological secretion pattern of cortisol. A novel dual-release formulation of hydrocortisone, recently approved by EMEA, represents an advancement in the optimization of the clinical management of patients with adrenal insufficiency. Future clinical trials of immunomodulation or immunoprevention will test the possibility to delay (or prevent) the autoimmune destruction of the adrenal gland in autoimmune Addison’s disease.
引用
收藏
页码：514 / 528
页数：14
相关论文
共 802 条
  • [21] Vince FP(1999)On the front of X-linked adrenoleukodystrophy Neurochem. Res. 24 515-182
  • [22] Løvas K(2007)DAX1: increasing complexity in the roles of this novel nuclear receptor Mol. Cell. Endocrinol. 265–266 179-126
  • [23] Husebye ES(1999)A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans Nat. Genet. 22 125-462
  • [24] Betterle C(1993)Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor Lancet 341 461-2066
  • [25] Dal Pra C(1996)Linkage of the gene for the triple A syndrome to chromosome 12q13 near the type II keratin gene cluster Hum. Mol. Genet. 5 2061-692
  • [26] Mantero F(1996)Oxidative phosphorylation defect associated with primary adrenal insufficiency J. Pediatrics 128 688-384
  • [27] Zanchetta R(1999)Adrenal insufficiency in Smith-Lemli-Opitz syndrome Am. J. Med. Genet. 82 382-4608
  • [28] Falorni A(2005)Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal J. Clin. Endocrinol. Metab. 92 4602-475
  • [29] Brozzetti A(1988)The natural history of adrenal function in autoimmune patients with adrenal autoantibodies J. Endocrinol. 117 467-1007
  • [30] Calcinaro F(1993)Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies J. Clin. Endocrinol. Metab. 76 1002-938
12345678910